ReviewThe journal of venomous animals and toxins including tropical diseases2017
Antiviral activity of animal venom peptides and related compounds.
Review in The journal of venomous animals and toxins including tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- RNF213 isoform 2 restricts Zika virus through antiviral signaling and viral protein degradation.iScience · 2026Article
- Peptides derived from exocrine secretions of venomous animals used as traditional Chinese "worm" medicines.Zoological research · 2026Review
- Computational discovery of SARS-CoV-2 viral entry inhibitory peptides fromFrontiers in bioinformatics · 2026Article
- From Discovery to the Future Medical Applications of Venom-derived Analgesic Peptides for the Treatment of Peripheral Pains.Current pharmaceutical design · 2026Review
- Next-generation antiviral peptides: AI-driven design, translational delivery platforms, and future therapeutic directions.Virus research · 2025Review
- Antimicrobial peptides for anticancer and antiviral therapy: last promising update.Discover oncology · 2025Review
- Article
- Design of Natterins-based peptides improves antimicrobial and antiviral activities.Biotechnology reports (Amsterdam, Netherlands) · 2025Article
- Exploiting venom toxins in paratransgenesis to prevent mosquito-borne disease.Parasites & vectors · 2025Review
- Characterization ofFrontiers in pharmacology · 2025Article
- Scorpion (Buthus martensii Karsch) in Chinese medicine: a review of traditional uses, chemical constituents, pharmacology, and toxicology.Frontiers in pharmacology · 2025Review
- Biomedical and Biotechnological Potential of Animal Venoms:Current medicinal chemistry · 2025Review
- Molecular docking of eleven snake venom peptides targeting human immunodeficiency virus capsid glycoprotein as inhibitors.Open veterinary journal · 2024Article
- Biochemical Characterisation andTropical life sciences research · 2024Article
- Article
- Anti-Herpes Simplex Virus and Anti-Inflammatory Activities of the Melittin Peptides Derived fromInsects · 2024Article
- Diverse RNA viruses in the venom-related microenvironment of different animal phyla.Virus evolution · 2024Article
- Study of alloferon, a novel immunomodulatory antimicrobial peptide (AMP), and its analogues.Frontiers in pharmacology · 2024Review
- Antiviral attributes of bee venom as a possible therapeutic approach against SARS-CoV-2 infection.Future virology · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viruses exhibit rapid mutational capacity to trick and infect host cells, sometimes assisted through virus-coded peptides that counteract host cellular immune defense. Although a large number of compounds have been identified as inhibiting various viral infections and disease progression, it is urgent to achieve the discovery of more effective agents. Furthermore, proportionally to the great variety of diseases caused by viruses, very few viral vaccines are available, and not all are efficient. Thus, new antiviral substances obtained from natural products have been prospected, including those derived from venomous animals. Venoms are complex mixtures of hundreds of molecules, mostly peptides, that present a large array of biological activities and evolved to putatively target the biochemical machinery of different pathogens or host cellular structures. In addition, non-venomous compounds, such as some body fluids of invertebrate organisms, exhibit antiviral activity. This review provides a panorama of peptides described from animal venoms that present antiviral activity, thereby reinforcing them as important tools for the development of new therapeutic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.